Product Information
PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE is a generic product labeled by Prasco Laboratories, priced at $3.0564 per EA under NDC 66993078130. Its NADAC has been published 59 times since Aug 20, 2025.
FDA first approved this application on Jul 17, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5; 46 mg/1; mg/1
Manufacturer
Prasco LaboratoriesNDC
66993078130
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDE; TOPIRAMATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022580FDA Approved
7/17/2012
TE Code
AB
On Market Since
6/1/2025
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE has been published 59 times since Aug 20, 2025, and over the history we have for it it has declined 34.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.0564 per EA |
|---|---|
| All-time high | $4.6508 (Sep 10, 2025) |
| All-time low | $3.0564 (Sep 23, 2026) |
| 52-week high | $3.9883 |
| 52-week low | $3.0564 |
| Median price | $3.3727 |
| Average price | $3.5421 |
| Largest weekly change | -14.2% (Sep 17, 2025) |
| Weeks tracked | 59 |
| Tracking since | Aug 20, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Prasco Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
phentermine and topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE, manufactured by Prasco Laboratories, is $3.0564 per EA (NDC 66993078130), effective Sep 30, 2026.
How has the price of PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE has declined 34.3%. It has been tracked across 59 weekly CMS publications since Aug 20, 2025.
What are the highest and lowest recorded NADAC prices for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
Since Aug 20, 2025, the NADAC for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE has ranged from a low of $3.0564 (Sep 23, 2026) to a high of $4.6508 (Sep 10, 2025), with a median of $3.3727 per EA.
Are there cheaper alternatives to PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE (NDC 66993078130) is labeled by Prasco Laboratories, and CMS classifies it as a generic product.